STAT+: Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
The ouster of the Food and Drug Administration\u2019s chief regulator of cell and gene therapies earlier this week came immediately after a disagreement with her boss over the review of a cell therapy for Duchenne muscular dystrophy, STAT has learned.\u00a0<\/p>\n
The regulator, Nicole Verdun, had scheduled an advisory committee meeting to review the therapy developed by Capricor Therapeutics. But Vinay Prasad, director of the FDA\u2019s Center for Biologics Evaluation and Research, was skeptical of the treatment and decided unilaterally to cancel the meeting, according to a person familiar with the matter.\u00a0\u00a0<\/p>\n
At the same time, there had been long-simmering tensions over Verdun\u2019s management style, according to others familiar with the matter, raising further questions about the precise reason she was placed on leave.\u00a0<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n